Gastro-esophageal Reflux Disease (GERD) Completed Phase 2 Trials for Arbaclofen Placarbil (DB08892)

Also known as: Esophageal Reflux / Gastroesophageal Reflux Disease / Gastrooesophageal reflux disease / Gastro-Oesophageal Reflux Disease / Gastro-esophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD Gastroesophageal Reflux Disease / GERD (Gastroesophageal Reflux Disease) / GERD / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00978016A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)Treatment
NCT00838396A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux DiseaseTreatment